HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 276, Issue 52, 49142-49147, December 28, 2001

This Article Full Text Full Text (PDF) All Versions of this Article: 276/52/49142    most recent M104879200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, G. Articles by Pillarisetti, S. Search for Related Content PubMed PubMed Citation Articles by Chen, G. Articles by Pillarisetti, S. Social Bookmarking                      What's this?

A Protective Role for Kidney Apolipoprotein E
REGULATION OF MESANGIAL CELL PROLIFERATION AND MATRIX EXPANSION^*

Guangping Chen, Latha Paka, Yuko Kako^§, Pravin Singhal^¶, Wenlan Duan, and Sivaram Pillarisetti^**

From the  Department of Radiation Oncology and ^¶ Medicine, North Shore-Long Island Jewish Health System, Manhasset, New York 11030, the ^§ Division of Preventive Medicine, Department of Medicine, Columbia University, New York, New York 10032, and the  Reddy US Therapeutics, Norcross, Georgia 30071

Mesangial expansion is a key feature in the pathogenesis of numerous renal diseases involving the glomerulus. Studies indicate that mutations in apolipoprotein E (apoE) might independently contribute to kidney dysfunction. Although the role of apoE as an atheroprotective molecule is well established, its role in kidney is unclear. In this study, we sought to explore whether apoE has a protective function in kidney. Northern blotting and reverse transcriptase-polymerase chain reaction showed apoE expression in kidney, and mesangial cell is a major source of apoE in kidney. In the kidneys of 14-16-month-old apoE-null mice, hematoxylin-eosin (HE) staining revealed increased mesangial cell proliferation and matrix formation compared with wild type mice or apoB-overexpressing mice, which have elevated plasma cholesterol and triglycerides. These data suggest that lack of apoE, rather than hyperlipidemia, contributes to increased mesangial expansion. We isolated mesangial cells from mouse kidney and determined the effect of apoE on cell growth. ApoE (E3, 10 µg/ml) completely inhibited serum, platelet-derived growth factor (10 ng/ml), as well as low density lipoprotein-induced mesangial cell proliferation. Among the three isoforms, E3 was found to be most effective in inhibiting mesangial cell proliferation. ApoE did not show any cytotoxic effect, and moreover, inhibited mesangial cell apoptosis induced by oxidized low density lipoprotein. These data suggest that apoE regulates growth as well as survival of mesangial cells. We previously showed that apoE induces matrix heparan sulfate proteoglycan (HSPG) in vascular cells, which has an antiproliferative effect. Similarly, apoE induced the mesangial matrix HSPG. Perlecan is the major HSPG of mesangial matrix and subendothelial space, and consistent with this, blockade of perlecan reversed the antiproliferative effect of apoE. Immunohistochemistry revealed reduced staining of perlecan in kidney from apoE-null mice. Because the loss of anionic HSPG in the basement membrane and mesangial matrix is associated with disruption of filtration barrier, these data suggest a novel role for kidney apoE in preserving the filtration barrier. In summary, apoE has a protective function in kidney as an autocrine regulator of mesangial expansion and kidney function.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C. Doorenbos, S.-W. Tsaih, S. Sheehan, N. Ishimori, G. Navis, G. Churchill, K. DiPetrillo, and R. Korstanje Quantitative Trait Loci for Urinary Albumin in Crosses Between C57BL/6J and A/J Inbred Mice in the Presence and Absence of Apoe Genetics, May 1, 2008; 179(1): 693 - 699. [Abstract] [Full Text] [PDF]

				M. Kinomura, H. Sugiyama, T. Saito, A. Matsunaga, K.-e. Sada, M. Kanzaki, Y. Takazawa, Y. Maeshima, H. Yanai, and H. Makino A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy Nephrol. Dial. Transplant., February 1, 2008; 23(2): 751 - 756. [Full Text] [PDF]

				F. Michel, S. Simonet, C. Vayssettes-Courchay, F. Bertin, P. Sansilvestri-Morel, F. Bernhardt, J. Paysant, J.-S. Silvestre, B. I. Levy, M. Feletou, et al. Altered TP receptor function in isolated, perfused kidneys of nondiabetic and diabetic ApoE-deficient mice Am J Physiol Renal Physiol, January 1, 2008; 294(1): F120 - F129. [Abstract] [Full Text] [PDF]

				C. C. Hsu, W. H. L. Kao, J. Coresh, J. S. Pankow, J. Marsh-Manzi, E. Boerwinkle, and M. S. Bray Apolipoprotein E and Progression of Chronic Kidney Disease JAMA, June 15, 2005; 293(23): 2892 - 2899. [Abstract] [Full Text] [PDF]

				H. Sultmann, A. v. Heydebreck, W. Huber, R. Kuner, A. Buness, M. Vogt, B. Gunawan, M. Vingron, L. Fuzesi, and A. Poustka Gene Expression in Kidney Cancer Is Associated with Cytogenetic Abnormalities, Metastasis Formation, and Patient Survival Clin. Cancer Res., January 15, 2005; 11(2): 646 - 655. [Abstract] [Full Text] [PDF]

				Y.-C. Chen, G. Pohl, T.-L. Wang, P. J. Morin, B. Risberg, G. B. Kristensen, A. Yu, B. Davidson, and I.-M. Shih Apolipoprotein E Is Required for Cell Proliferation and Survival in Ovarian Cancer Cancer Res., January 1, 2005; 65(1): 331 - 337. [Abstract] [Full Text] [PDF]

				L. Yue, N. Rasouli, G. Ranganathan, P. A. Kern, and T. Mazzone Divergent Effects of Peroxisome Proliferator-activated Receptor {gamma} Agonists and Tumor Necrosis Factor {alpha} on Adipocyte ApoE Expression J. Biol. Chem., November 12, 2004; 279(46): 47626 - 47632. [Abstract] [Full Text] [PDF]

				E. N. Liberopoulos, G. A. Miltiadous, M. Cariolou, R. Kalaitzidis, K. C. Siamopoulos, and M. S. Elisaf Influence of apolipoprotein E polymorphisms on serum creatinine levels and predicted glomerular filtration rate in healthy subjects Nephrol. Dial. Transplant., August 1, 2004; 19(8): 2006 - 2012. [Abstract] [Full Text] [PDF]

				M. Lassila, K. K. Seah, T. J. Allen, V. Thallas, M. C. Thomas, R. Candido, W. C. Burns, J. M. Forbes, A. C. Calkin, M. E. Cooper, et al. Accelerated Nephropathy in Diabetic Apolipoprotein E-Knockout Mouse: Role of Advanced Glycation End Products J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2125 - 2138. [Abstract] [Full Text] [PDF]

				U. Vitt, D. Gietzen, K. Stevens, J. Wingrove, S. Becha, S. Bulloch, J. Burrill, N. Chawla, J. Chien, M. Crawford, et al. Identification of Candidate Disease Genes by EST Alignments, Synteny, and Expression and Verification of Ensembl Genes on Rat Chromosome 1q43-54 Genome Res., April 1, 2004; 14(4): 640 - 650. [Abstract] [Full Text] [PDF]

				S.-i. Araki, D. Koya, T. Makiishi, T. Sugimoto, M. Isono, R. Kikkawa, A. Kashiwagi, and M. Haneda APOE Polymorphism and the Progression of Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes: Results of a prospective observational follow-up study Diabetes Care, August 1, 2003; 26(8): 2416 - 2420. [Abstract] [Full Text] [PDF]